中国医学创新2025，Vol.22Issue(35)：58-62,5.DOI:10.3969/j.issn.1674-4985.2025.35.014
培美曲塞联合卡铂治疗驱动基因阴性非小细胞肺癌患者的临床效果
Clinical Efficacy of Pemetrexed Combined with Carboplatin in Patients with Driver Gene-Negative Non-Small Cell Lung Cancer
摘要
Abstract
Objective:To compare the efficacy,safety,and quality of life between Pemetrexed combined with Carboplatin and Gemcitabine combined with Carboplatin regimens in patients with driver gene-negative non-small cell lung cancer,to provide evidence for clinical chemotherapy selection.Method:A total of 107 patients with driver gene negative non-small cell lung cancer in the First People's Hospital of Jingdezhen from January 2020 to December 2024 were selected and divided into an AP group(n=50)and a GP group(n=57)according to the difference in treatment plan.The AP group received Pemetrexed and Carboplatin,while the GP group received Gemcitabine and Carboplatin,one cycle lasted for 21 days,and at least two cycles were completed.Therapeutic effect of tumor was evaluated using RECIST 1.1 criteria,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 72-4(CA72-4)]were measured,adverse events were assessed with common terminology criteria for adverse events(CTCAE)5.0,and quality of life was evaluated via the SF-36.Result:The disease control rate in the AP group was significantly higher compared to the GP group(P<0.05).Compared with those before treatment,the levels of CEA,CA19-9 and CA72-4 decreased in both groups after treatment,those in the AP group were even lower than those in the GP group(P<0.05).The incidence of adverse reactions in the AP group was lower than that in the GP group(P<0.05).After treatment,the scores of all items of SF-36 in AP group and GP group were higher than those before treatment(P<0.05),while the scores of all items of SF-36 in the AP group were higher than those in the GP group(P<0.05).Conclusion:The Pemetrexed combined with Carboplatin regimen has demonstrated superior efficacy,more favorable safety profile and higher quality of life in patients with driver gene-negative non-small cell lung cancer,suggesting it as a preferred chemotherapy option.关键词
非小细胞肺癌/培美曲塞/吉西他滨/卡铂Key words
Non-small cell lung cancer/Pemetrexed/Gemcitabine/Carboplatin引用本文复制引用
黎鹏,雷蕾,舒志勇..培美曲塞联合卡铂治疗驱动基因阴性非小细胞肺癌患者的临床效果[J].中国医学创新,2025,22(35):58-62,5.基金项目
景德镇市科技计划项目(20211SFZC002) （20211SFZC002）
